News & Updates

Show Multimedia Only

Olmesartan-amlodipine single-pill + rosuvastatin reduces SBP, LDL-C in concomitant hypertension, dyslipidaemia

29 Jan 2022 by

Treatment with a single-pill combination (SPC) drug, composed of olmesartan and amlodipine, plus a separate dose of rosuvastatin led to significantly reduced systolic blood pressure (SBP) and low-density lipoprotein cholesterol (LDL-C) levels in patients with concomitant hypertension and dyslipidaemia, according to the LEISURE* trial.

29 Jan 2022

Erenumab effective for migraine regardless of aura status

28 Jan 2022 by

In a post hoc analysis, use of the anti-CGRP* receptor monoclonal antibody erenumab led to reduced migraine frequency and AMSM** days in individuals with migraine with and without a history of aura.

28 Jan 2022

Dronedarone better than sotalol in post-AF ablation setting

27 Jan 2022 by

Treatment with dronedarone following atrial fibrillation (AF) ablation appears to lead to a reduced risk of cardiovascular hospitalization as well as lower rates of combined proarrhythmia when compared with sotalol, as shown in a recent study.

27 Jan 2022

Menopausal hormone therapy carries increased cutaneous melanoma risk

27 Jan 2022

The use of unopposed oestrogen in menopausal women may contribute to a heightened risk of cutaneous melanoma, a study has found.

27 Jan 2022

Early 3-day remdesivir course may prevent COVID-19 hospitalization, death

26 Jan 2022 by

An early, 3-day regimen of remdesivir may prevent hospitalization and death in patients with COVID-19 who are at risk for disease progression, according to results of the PINETREE study.

26 Jan 2022

Obsessive-compulsive symptoms in clozapine-treated patients take a toll on their wellbeing

26 Jan 2022

Obsessive-compulsive symptoms appear to frequently occur among schizophrenic patients receiving treatment with clozapine, and these symptoms exert a negative effect on the patients’ wellbeing, a study reports.

26 Jan 2022

Mirikizumab improves disease, symptom severity in patients with Crohn’s disease

26 Jan 2022 by

Treatment with the anti-interleukin-23p19 inhibitor mirikizumab led to significant improvements in patient-assessed disease severity and activity, as well as abdominal pain, in individuals with moderate-to-severe active Crohn’s disease, according to phase II data presented at the Crohn’s and Colitis Congress (CCC) 2022.

26 Jan 2022

Second-line tisagenlecleucel renders no EFS benefit in aggressive B-cell lymphoma

25 Jan 2022 by

The anti-CD19 chimeric antigen receptor (CAR) T-cell treatment tisagenlecleucel did not improve event-free survival (EFS) compared with standard care in patients refractory or who had progressed following first-line therapy for aggressive B-cell non-Hodgkin’s lymphoma, results of the phase III BELINDA trial showed.

25 Jan 2022

Investigative drug for ulcerative colitis passes muster in early trial

25 Jan 2022

The orally administered, small molecule, gut-targeted stabiliser of hypoxia-inducible factor-1α (HIF-1α) GB004 appears to improve disease activity in patients with ulcerative colitis, with the drug being well-tolerated, according to the results of a phase Ib trial.

25 Jan 2022

Esaxerenone produces favourable night-time BP-lowering effect in Asians

24 Jan 2022 by

The novel highly selective mineralocorticoid receptor blocker esaxerenone holds promise in the treatment of nocturnal hypertension, yielding substantial reductions in night-time blood pressure (BP), especially in Japanese patients with a riser pattern, as well as in N-terminal pro B-type natriuretic peptide (NT-proBNP) levels, according to a post hoc analysis of a phase III study.

24 Jan 2022

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Olmesartan-amlodipine single-pill + rosuvastatin reduces SBP, LDL-C in concomitant hypertension, dyslipidaemia

Erenumab effective for migraine regardless of aura status

Dronedarone better than sotalol in post-AF ablation setting

Menopausal hormone therapy carries increased cutaneous melanoma risk

Early 3-day remdesivir course may prevent COVID-19 hospitalization, death

Obsessive-compulsive symptoms in clozapine-treated patients take a toll on their wellbeing

Mirikizumab improves disease, symptom severity in patients with Crohn’s disease

Second-line tisagenlecleucel renders no EFS benefit in aggressive B-cell lymphoma

Investigative drug for ulcerative colitis passes muster in early trial

Esaxerenone produces favourable night-time BP-lowering effect in Asians